Belgian-based pharmaceutical firm UCB plans to invest $47.5 million to expand its U.S. headquarters campus in Smyrna, Georgia, bringing 100 new high-paying jobs to Cobb County.

UCB is a global biopharmaceutical company focused on developing treatments for people living with severe immunological and neurological conditions, including epilepsy, Parkinson’s disease, rheumatoid arthritis, lupus, Crohn’s disease and osteoporosis. As the largest biopharmaceutical company in Georgia, its U.S. headquarters currently consists of a 47-acre corporate campus in Smyrna. The planned $47.5 million investment includes $23.5 million to repurpose an existing building and add a new parking area. After completion, the company would add 100 new jobs on top of its current 400 workers with average annual incomes of $100,000 per year.

“UCB’s long-term commitment to creating jobs and promoting growth within Cobb County and the City of Smyrna should be commended,” said Dana Johnson, executive director of SelectCobb. “The jobs they are creating are high-quality jobs that will have incredible financial impact on Smyrna and the surrounding areas—and keep Cobb County Georgia’s number one business destination.”

Building plans are currently under review. Upon approval, construction could start this summer and would take approximately 18 months. Phases two and three are expected to add $24 million more in construction and infrastructure investment, though no timeline has been announced yet for this expansion.